Pfizer Inc. (NYSE: PFE) presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE